학술논문
SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.
Document Type
Article
Author
Hoff, Fieke W.; Goksu, Suleyman Y.; Premnath, Naveen; Patel, Prapti A.; Ikpefan, Ruth; Kaur, Gurbakhash; Vusirikala, Madhuri; Bat, Taha; Weina Chen; Geethakumari, Praveen Ramakrishnan; Anderson Jr., Larry D.; Awan, Farrukh T.; Collins, Robert H.; Weinberg, Olga K.; Muthukumar, Alagarraju; Chung, Stephen S.; Madanat, Yazan F.
Source
Subject
*HEMATOLOGIC malignancies
*ANTIBODY formation
*COVID-19 vaccines
*SARS-CoV-2
*IMMUNOGLOBULIN G
*
*
*
*
Language
ISSN
1840-1848
Abstract
Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients. [ABSTRACT FROM AUTHOR]